Cite
HARVARD Citation
Moyano‐Galceran, L. et al. (2020). Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. EMBO molecular medicine. 12 (4), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Moyano‐Galceran, L. et al. (2020). Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. EMBO molecular medicine. 12 (4), p. n/a. [Online].